Friday, June 19 2026

Pharmaceutical and healthcare sectors: Govt steps up efforts to attract Chinese investment
Pakistan is stepping up efforts to attract Chinese investment into its pharmaceutical and healthcare sectors, with nearly 60 leading Chinese companies participating in investment promotion events in Beijing ahead of the Pakistan–China B2B Pharmaceutical, Healthcare and Biotechnology Investment Conference scheduled to be held in Karachi on July 17-18. The Embassy of Pakistan in Beijing organized two investment promotion events on Thursday in collaboration with the China Overseas Development Association (CODA) and IBI GoulianGufen to mobilize Chinese investors for the upcoming conference. The events brought together almost 60 Chinese enterprises, including more than 40 companies at the embassy and another 17 firms at an event in Beijing’s Fengtai District.
Related news categories: business economic-indicators pharma psx stock-exchanges

Monday, June 01 2026

First Pakistani pharma company recognized by PIC/S for injections, eye drops
In a historical development, a Pakistan-based pharmaceutical company has secured the prestigious PIC/S recognition for having matched global quality standards for producing medicines in injection form and eye drops in line with the international benchmarks, claiming to become the first company in the country to receive the international accreditation for its sterile manufacturing facility. The global certification has opened doors for the company to expand its circle of exports to regulated high-end markets including Malaysia, Africa, Central Asia and ASEAN countries from Pakistan. ATCO Group says it is the first and only pharmaceutical company in Pakistan to have its sterile manufacturing facility compliant with internationally harmonized PIC/S GMP standards.
Related news categories: business economic-indicators misc pharma

Monday, May 25 2026

Deregulation of non-essential medicines leads to 34pc increase in pharma exports
Deregulation of non-essential medicines in 2024 has led to a 34 percent increase in pharmaceutical exports, improved medicine availability, expansion of internationally certified manufacturing facilities and higher tax contributions, while any reversal of the policy could result in an industrial crisis and loss of investor confidence, pharmaceutical industry officials said. According to industry estimates, pharmaceutical exports increased from around USD336 million before deregulation to nearly USD450 million in 2025, while manufacturers also expanded investment in WHO, PIC/S and EU GMP compliant facilities aimed at accessing regulated international markets.
Related news categories: business economic-indicators misc pharma